How does 539524's PE Ratio compare to its peers?

539524 is good value based on its Price-To-Earnings Ratio (62.8x) compared to the peer average (65.9x).

How does 539524's PE Ratio compare vs other companies in the IN Healthcare Industry?

539524 is expensive based on its Price-To-Earnings Ratio (62.8x) compared to the Indian Healthcare industry average (42.6x).

What is 539524's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

539524 is expensive based on its Price-To-Earnings Ratio (62.8x) compared to the estimated Fair Price-To-Earnings Ratio (50.9x).

What is the Fair Price of 539524 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

539524 (₹3028.25) is trading above our estimate of [[fair value]] (₹1322.68)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is less than 20% higher than the current share price.

Dr. Lal PathLabs (BSE:539524) - Stock Price, News & Analysis

539524 Stock Overview

Operates laboratories for carrying out pathological investigations in India and internationally. More details

539524 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	3/6
Past Performance	5/6
Financial Health	5/6
Dividends	3/6

Rewards

Earnings are forecast to grow 13.61% per year

Earnings grew by 33.2% over the past year

Risk Analysis

Significant insider selling over the past 3 months

Unstable dividend track record

Dr. Lal PathLabs Limited Competitors

Metropolis Healthcare

NSEI:METROPOLIS

₹103.3b

Vijaya Diagnostic Centre

NSEI:VIJAYA

₹117.8b

Thyrocare Technologies

BSE:539871

₹51.4b

Krsnaa Diagnostics

NSEI:KRSNAA

₹30.2b

Price History & Performance

Summary of all time highs, changes and price drops for Dr. Lal PathLabs
Historical stock prices
Current Share Price	₹3,028.25
52 Week High	₹3,645.00
52 Week Low	₹1,943.20
Beta	0.30
11 Month Change	-8.72%
3 Month Change	-8.38%
1 Year Change	15.98%
33 Year Change	-11.63%
5 Year Change	90.55%
Change since IPO	267.44%

Recent updates

Shareholder Returns

	539524	IN Healthcare	IN Market
7D	2.5%	0.8%	0.3%
1Y	16.0%	36.4%	27.3%

Return vs Industry: 539524 underperformed the Indian Healthcare industry which returned 36.4% over the past year.

Return vs Market: 539524 underperformed the Indian Market which returned 27.3% over the past year.

Price Volatility

Is 539524's price volatile compared to industry and market?
539524 volatility
539524 Average Weekly Movement	3.4%
Healthcare Industry Average Movement	5.5%
Market Average Movement	6.1%
10% most volatile stocks in IN Market	9.2%
10% least volatile stocks in IN Market	4.0%

Stable Share Price: 539524 has not had significant price volatility in the past 3 months compared to the Indian market.

Volatility Over Time: 539524's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1949	4,099	Shankha Banerjee	www.lalpathlabs.com

Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers training programs.

Dr. Lal PathLabs Limited Fundamentals Summary

How do Dr. Lal PathLabs's earnings and revenue compare to its market cap?
539524 fundamental statistics
Market cap	₹252.12b
Earnings (TTM)	₹4.01b
Revenue (TTM)	₹23.46b

62.8x

P/E Ratio

10.7x

P/S Ratio

Is 539524 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
539524 income statement (TTM)
Revenue	₹23.46b
Cost of Revenue	₹9.89b
Gross Profit	₹13.57b
Other Expenses	₹9.56b
Earnings	₹4.01b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	48.18
Gross Margin	57.84%
Net Profit Margin	17.11%
Debt/Equity Ratio	2.0%

How did 539524 perform over the long term?

See historical performance and comparison

Dividends

0.6%

Current Dividend Yield

62%

Payout Ratio

Does 539524 pay a reliable dividends?

See 539524 dividend history and benchmarks

When do you need to buy 539524 by to receive an upcoming dividend?
Dr. Lal PathLabs dividend dates
Ex Dividend Date	Nov 05 2024
Dividend Pay Date	Nov 22 2024
Days until Ex dividend	17 days
Days until Dividend pay date	0 days

Does 539524 pay a reliable dividends?

See 539524 dividend history and benchmarks

539524 Stock Overview

Rewards

Risk Analysis

Dr. Lal PathLabs Limited Competitors

NSEI:METROPOLIS

₹103.3b

NSEI:VIJAYA

₹117.8b

BSE:539871

₹51.4b

NSEI:KRSNAA

₹30.2b

Price History & Performance

Recent News & Updates

Company Secretary & Compliance Officer recently sold ₹1.7m worth of stock

Upcoming dividend of ₹6.00 per share

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Dr. Lal Pathlabs Limited Announces Stepping Down of Dr. Om Prakash Manchanda as Managing Director, Effective March 31, 2025

Dr. Lal PathLabs Limited to Report Q2, 2025 Results on Oct 23, 2024

MD & Director recently sold ₹28m worth of stock

Recent updates

Company Secretary & Compliance Officer recently sold ₹1.7m worth of stock

Upcoming dividend of ₹6.00 per share

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Dr. Lal Pathlabs Limited Announces Stepping Down of Dr. Om Prakash Manchanda as Managing Director, Effective March 31, 2025

Dr. Lal PathLabs Limited to Report Q2, 2025 Results on Oct 23, 2024

MD & Director recently sold ₹28m worth of stock

Price target increased by 7.2% to ₹2,794

First quarter 2025 earnings: EPS exceeds analyst expectations

Dr. Lal PathLabs Limited Approves Interim Dividend for the Fiscal Year 2024-25

Dr. Lal PathLabs Limited to Report Q1, 2025 Results on Aug 07, 2024

Non Executive Director recently sold ₹14m worth of stock

MD & Director recently sold ₹20m worth of stock

MD & Director recently sold ₹28m worth of stock

MD & Director recently sold ₹37m worth of stock

Upcoming dividend of ₹6.00 per share

MD & Director recently sold ₹29m worth of stock

MD & Director recently sold ₹36m worth of stock

Dr. Lal PathLabs Limited, Annual General Meeting, Jun 29, 2024

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Dr. Lal PathLabs Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024

Dr. Lal PathLabs Limited to Report Q4, 2024 Results on May 10, 2024

Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer, Effective May 9, 2024

MD & Director recently sold ₹33m worth of stock

MD & Director recently sold ₹23m worth of stock

MD & Director recently sold ₹43m worth of stock

Upcoming dividend of ₹12.00 per share at 0.7% yield

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Dr. Lal PathLabs Limited Approves Second Interim Dividend for the Fiscal Year 2023-24

Dr. Lal PathLabs Limited to Report Q3, 2024 Results on Feb 01, 2024

Chief Executive Officer recently sold ₹7.6m worth of stock

Chief Executive Officer recently sold ₹2.6m worth of stock

Non Executive Director recently sold ₹7.8m worth of stock

Price target increased by 8.0% to ₹2,353

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Dr. Lal PathLabs Limited to Report Q2, 2024 Results on Nov 02, 2023

MD & Director recently sold ₹43m worth of stock

Dr. Lal Pathlabs Limited Approves to Declare Final Dividend for the Financial Year Ended March 31, 2023

Dr. Lal PathLabs Limited Announces Change in Directorate

Dr. Lal PathLabs Limited Announces Change in Directorate

MD & Director recently sold ₹32m worth of stock

Upcoming dividend of ₹12.00 per share at 0.5% yield

Price target increased by 7.2% to ₹2,091

Dr. Lal PathLabs Limited, Annual General Meeting, Sep 12, 2023

Dr. Lal Pathlabs Limited Proposes Interim Dividend for the Financial Year 2023-24

First quarter 2024 earnings released: EPS: ₹9.95 (vs ₹6.97 in 1Q 2023)

MD & Director recently sold ₹41m worth of stock

MD & Director recently sold ₹43m worth of stock

Dr. Lal Pathlabs Limited Approves Appointment of Vinay Gujral as Company Secretary

Full year 2023 earnings: EPS and revenues miss analyst expectations

MD & Director recently sold ₹14m worth of stock

MD & Director recently sold ₹48m worth of stock

MD & Director recently sold ₹41m worth of stock

Rajat Kalra Resigns as Company Secretary and Compliance Officer of Dr. Lal Pathlabs Limited, Effective on or Before May 04, 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Dr. Lal PathLabs Limited (NSEI:LALPATHLAB) agreed to acquire additional 10% stake in Aprl Pathlabs Private Limited for INR 7.5 million.

Dr. Lal PathLabs Limited to Report Q3, 2023 Results on Feb 02, 2023

Chief Executive Officer recently sold ₹3.6m worth of stock

MD & Director recently sold ₹48m worth of stock

MD & Director recently sold ₹61m worth of stock